Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

GT Biopharma Inc
Healthcare
P/NCAV
0.66x
Ticker
GTBP
Exchange
NASDAQ
Country
United States
Close
3.65 $
Mkt Cap
4.9M $
EV
3.8M $
NCAV Burn Rate
35.8%
Current Ratio
2.12
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
-0.3x
EV/FCF
-0.4x
Dilution
243.7% p.A
Total Net Income
-591.1M $
Cheapness
14.0%
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer (NK) cells. The Company is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus (HIV). Its GTB-3550 is the first-generation TriKE product candidate which was a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15, all connected by small peptide linkers.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average